Show simple item record

dc.contributor.authorNdukwe, HC
dc.contributor.authorNishtala, PS
dc.date.accessioned2021-05-04T23:21:48Z
dc.date.available2021-05-04T23:21:48Z
dc.date.issued2016
dc.identifier.issn0271-0749
dc.identifier.doi10.1097/JCP.0000000000000597
dc.identifier.urihttp://hdl.handle.net/10072/404143
dc.description.abstractConsensus guidelines which are applicable in New Zealand and worldwide recommend that the duration of exposure to antipsychotics not exceed 12 weeks, unless justified for mental illnesses like schizophrenia and severe psychotic symptoms which require longer treatment. There has been limited information on time-to-first discontinuation (TTFD) for second-generation antipsychotics (SGAs) in a real world population setting in older people. The study objective was to compare TTFD, adherence, and persistence for individual SGA new users among people 65 years and older. A cohort of 30,297 SGA new users was followed up for antipsychotic discontinuation from January 1, 2006, to December 31, 2012. Data for oral formulations were extracted using health care databases from the New Zealand Ministry of Health. The TTFD, adherence, and persistence were defined using (dispensing gap ≥ 91 days, variable medication possession ratio ≥ 0.8, and gap duration < 91 days between refills), respectively. Kaplan-Meier curves and Cox regression analysis were used to estimate and adjust for outcomes. The overall TTFD in SGA new users was 192.3 days (95% confidence interval [CI], 177.6-206.9), mean age at dispensing was 80.9 years (SD, 8.1 years), and 60.3% were women. The TTFD for was shortest for risperidone, 101.3 days (95% CI, 85.0-117.7; P = 0.03) compared with clozapine, 68.3 days (95% CI: 43.7, 92.9). The adjusted all-cause TTFD risk for risperidone, olanzapine, quetiapine, or ziprasidone (hazard ratios, 0.54, 0.29, 0.22, and 0.08, respectively) was significantly lower than clozapine. The TTFD risk in the nonadherent compared with the adherent group was more than 3 times.
dc.description.peerreviewedYes
dc.languageeng
dc.publisherOvid Technologies (Wolters Kluwer Health)
dc.relation.ispartofpagefrom649
dc.relation.ispartofpageto657
dc.relation.ispartofissue6
dc.relation.ispartofjournalJournal of Clinical Psychopharmacology
dc.relation.ispartofvolume36
dc.subject.fieldofresearchPharmacology and Pharmaceutical Sciences
dc.subject.fieldofresearchPsychology
dc.subject.fieldofresearchMedical and Health Sciences
dc.subject.fieldofresearchPsychology and Cognitive Sciences
dc.subject.fieldofresearchcode1115
dc.subject.fieldofresearchcode1701
dc.subject.fieldofresearchcode11
dc.subject.fieldofresearchcode17
dc.titleTime-to-First Discontinuation, Adherence and Persistence in New Users of Second-Generation Antipsychotics
dc.typeJournal article
dc.type.descriptionC1 - Articles
dcterms.bibliographicCitationNdukwe, HC; Nishtala, PS, Time-to-First Discontinuation, Adherence and Persistence in New Users of Second-Generation Antipsychotics, Journal of Clinical Psychopharmacology, 2016, 36 (6), pp. 649-657
dc.date.updated2021-05-04T23:21:09Z
gro.hasfulltextNo Full Text
gro.griffith.authorNdukwe, Henry C.


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record